Guinness Atkinson Asset Management Inc Has $5.68 Million Holdings in Danaher Corporation $DHR

Guinness Atkinson Asset Management Inc grew its holdings in Danaher Corporation (NYSE:DHR) by 9.3% during the 3rd quarter, Holdings Channel reports. The firm owned 30,515 shares of the conglomerate’s stock after purchasing an additional 2,585 shares during the period. Danaher makes up approximately 2.7% of Guinness Atkinson Asset Management Inc’s portfolio, making the stock its 20th biggest position. Guinness Atkinson Asset Management Inc’s holdings in Danaher were worth $5,678,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. Vanguard Group Inc. grew its stake in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after purchasing an additional 788,499 shares during the period. Geode Capital Management LLC lifted its stake in Danaher by 0.6% in the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock valued at $2,697,800,000 after buying an additional 81,670 shares during the period. Norges Bank bought a new position in Danaher during the second quarter worth about $1,979,503,000. Generation Investment Management LLP grew its position in shares of Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after buying an additional 1,787,522 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Danaher by 4.0% in the 2nd quarter. Franklin Resources Inc. now owns 4,822,442 shares of the conglomerate’s stock valued at $952,625,000 after acquiring an additional 186,357 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DHR shares. The Goldman Sachs Group reduced their price objective on shares of Danaher from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, January 29th. Wells Fargo & Company boosted their price target on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Danaher in a research report on Thursday, January 29th. Leerink Partners lifted their target price on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Finally, Jefferies Financial Group boosted their target price on Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Twenty equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $252.32.

Danaher Stock Down 1.7%

NYSE:DHR opened at $215.70 on Friday. The stock has a 50-day simple moving average of $229.81 and a 200 day simple moving average of $214.68. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $242.80. The company has a market cap of $152.36 billion, a PE ratio of 42.80, a PEG ratio of 2.97 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The company had revenue of $6.84 billion during the quarter, compared to analysts’ expectations of $6.79 billion. During the same period last year, the business earned $2.14 EPS. The business’s quarterly revenue was up 4.6% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s payout ratio is presently 25.40%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,248 shares of company stock valued at $6,609,663 in the last three months. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.